By Colin Kellaher
Galapagos's number-two executive, Thad Huston, is leaving the biotechnology company after just over two years on the job.
Galapagos on Tuesday said Huston, who joined the Belgium-based company in July 2023 as chief operating and financial officer from Gilead's Kite Pharma unit, plans to depart effective Aug. 1 to return to the U.S. for personal and professional reasons.
The company said it expects to announce Huston's successor in the coming months.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 15, 2025 06:06 ET (10:06 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。